Provider Continuity Prior to the Diagnosis of Advanced Lung Cancer and End-of-Life Care

Gulshan Sharma, Yue Wang, James E. Graham, Yong Fang Kuo, James Goodwin

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background:Little is known about the effect of provider continuity prior to the diagnosis of advanced lung cancer and end-of-life care.Methods:Retrospective analysis of 69,247 Medicare beneficiaries aged 67 years or older diagnosed with Stage IIIB or IV lung cancer between January 1, 1993 and December 31, 2005 who died within two years of diagnosis. We examined visit patterns to a primary care physician (PCP) and/or any provider one year prior to the diagnosis of advanced lung cancer as measures of continuity of care. Outcome measures were hospitalization, ICU use and chemotherapy use during the last month of life, and hospice use during the last week of life.Results:Seeing a PCP or any provider in the year prior to the diagnosis of advanced lung cancer increased the likelihood of hospitalization, ICU care, chemotherapy and hospice use during the end of life. Patients with 1-3, 4-7 or >7 visits to their PCP in the year prior to the diagnosis of lung cancer had 1.0 (reference), 1.08 (95% CI; 1.04-1.13), and 1.14 (95% CI; 1.08-1.19) odds of hospitalization during the last month of life, respectively. Odds of hospice use during the last week of life were higher in patients with visits to multiple PCPs (OR 1.10: 95% CI; 1.06-1.15) compared to those whose visits were all to the same PCP.Conclusion:Provider continuity in the year prior to the diagnosis of advanced lung cancer was not associated with lower use of aggressive care during end of life. Our study did not have information on patient preferences and result should be interpreted accordingly.

Original languageEnglish (US)
Article numbere74690
JournalPLoS One
Volume8
Issue number9
DOIs
StatePublished - Sep 3 2013

Fingerprint

Terminal Care
lung neoplasms
Lung Neoplasms
Primary Care Physicians
physicians
Intensive care units
Hospitalization
Hospices
Chemotherapy
drug therapy
Hospice Care
Drug Therapy
Continuity of Patient Care
Patient Preference
Medicare
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Provider Continuity Prior to the Diagnosis of Advanced Lung Cancer and End-of-Life Care. / Sharma, Gulshan; Wang, Yue; Graham, James E.; Kuo, Yong Fang; Goodwin, James.

In: PLoS One, Vol. 8, No. 9, e74690, 03.09.2013.

Research output: Contribution to journalArticle

@article{0a549771c9d54cfeb2da11cd45b9e730,
title = "Provider Continuity Prior to the Diagnosis of Advanced Lung Cancer and End-of-Life Care",
abstract = "Background:Little is known about the effect of provider continuity prior to the diagnosis of advanced lung cancer and end-of-life care.Methods:Retrospective analysis of 69,247 Medicare beneficiaries aged 67 years or older diagnosed with Stage IIIB or IV lung cancer between January 1, 1993 and December 31, 2005 who died within two years of diagnosis. We examined visit patterns to a primary care physician (PCP) and/or any provider one year prior to the diagnosis of advanced lung cancer as measures of continuity of care. Outcome measures were hospitalization, ICU use and chemotherapy use during the last month of life, and hospice use during the last week of life.Results:Seeing a PCP or any provider in the year prior to the diagnosis of advanced lung cancer increased the likelihood of hospitalization, ICU care, chemotherapy and hospice use during the end of life. Patients with 1-3, 4-7 or >7 visits to their PCP in the year prior to the diagnosis of lung cancer had 1.0 (reference), 1.08 (95{\%} CI; 1.04-1.13), and 1.14 (95{\%} CI; 1.08-1.19) odds of hospitalization during the last month of life, respectively. Odds of hospice use during the last week of life were higher in patients with visits to multiple PCPs (OR 1.10: 95{\%} CI; 1.06-1.15) compared to those whose visits were all to the same PCP.Conclusion:Provider continuity in the year prior to the diagnosis of advanced lung cancer was not associated with lower use of aggressive care during end of life. Our study did not have information on patient preferences and result should be interpreted accordingly.",
author = "Gulshan Sharma and Yue Wang and Graham, {James E.} and Kuo, {Yong Fang} and James Goodwin",
year = "2013",
month = "9",
day = "3",
doi = "10.1371/journal.pone.0074690",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - Provider Continuity Prior to the Diagnosis of Advanced Lung Cancer and End-of-Life Care

AU - Sharma, Gulshan

AU - Wang, Yue

AU - Graham, James E.

AU - Kuo, Yong Fang

AU - Goodwin, James

PY - 2013/9/3

Y1 - 2013/9/3

N2 - Background:Little is known about the effect of provider continuity prior to the diagnosis of advanced lung cancer and end-of-life care.Methods:Retrospective analysis of 69,247 Medicare beneficiaries aged 67 years or older diagnosed with Stage IIIB or IV lung cancer between January 1, 1993 and December 31, 2005 who died within two years of diagnosis. We examined visit patterns to a primary care physician (PCP) and/or any provider one year prior to the diagnosis of advanced lung cancer as measures of continuity of care. Outcome measures were hospitalization, ICU use and chemotherapy use during the last month of life, and hospice use during the last week of life.Results:Seeing a PCP or any provider in the year prior to the diagnosis of advanced lung cancer increased the likelihood of hospitalization, ICU care, chemotherapy and hospice use during the end of life. Patients with 1-3, 4-7 or >7 visits to their PCP in the year prior to the diagnosis of lung cancer had 1.0 (reference), 1.08 (95% CI; 1.04-1.13), and 1.14 (95% CI; 1.08-1.19) odds of hospitalization during the last month of life, respectively. Odds of hospice use during the last week of life were higher in patients with visits to multiple PCPs (OR 1.10: 95% CI; 1.06-1.15) compared to those whose visits were all to the same PCP.Conclusion:Provider continuity in the year prior to the diagnosis of advanced lung cancer was not associated with lower use of aggressive care during end of life. Our study did not have information on patient preferences and result should be interpreted accordingly.

AB - Background:Little is known about the effect of provider continuity prior to the diagnosis of advanced lung cancer and end-of-life care.Methods:Retrospective analysis of 69,247 Medicare beneficiaries aged 67 years or older diagnosed with Stage IIIB or IV lung cancer between January 1, 1993 and December 31, 2005 who died within two years of diagnosis. We examined visit patterns to a primary care physician (PCP) and/or any provider one year prior to the diagnosis of advanced lung cancer as measures of continuity of care. Outcome measures were hospitalization, ICU use and chemotherapy use during the last month of life, and hospice use during the last week of life.Results:Seeing a PCP or any provider in the year prior to the diagnosis of advanced lung cancer increased the likelihood of hospitalization, ICU care, chemotherapy and hospice use during the end of life. Patients with 1-3, 4-7 or >7 visits to their PCP in the year prior to the diagnosis of lung cancer had 1.0 (reference), 1.08 (95% CI; 1.04-1.13), and 1.14 (95% CI; 1.08-1.19) odds of hospitalization during the last month of life, respectively. Odds of hospice use during the last week of life were higher in patients with visits to multiple PCPs (OR 1.10: 95% CI; 1.06-1.15) compared to those whose visits were all to the same PCP.Conclusion:Provider continuity in the year prior to the diagnosis of advanced lung cancer was not associated with lower use of aggressive care during end of life. Our study did not have information on patient preferences and result should be interpreted accordingly.

UR - http://www.scopus.com/inward/record.url?scp=84883326245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883326245&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0074690

DO - 10.1371/journal.pone.0074690

M3 - Article

C2 - 24019974

AN - SCOPUS:84883326245

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e74690

ER -